Speakers and delegates at the International Expert Forum: Complement Therapeutics in Clinical Practice in Kidney Disease in Singapore As complement therapeutics expand across kidney diseases, how should clinicians decide when to use them, how to monitor response, and when to change or stop treatment? From September 16-18, 113 experts from 32 countries gathered in Singapore for...
Kidney International® Pegcetacoplan prophylaxis for recurrent C3 glomerulopathy with multifactorial genetic background C3 glomerulopathy (C3G) has a high risk of recurrence after kidney transplantation, and there is limited evidence on how best to prevent it. This case report describes a child with severe, early-onset C3G and a complex genetic background who received pegcetacoplan before and after a living-donor kidney transplant as prophylaxis...
Kidney International® (KI) Chronic Kidney Disease–Mineral and Bone Disorder: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference The 2023 KDIGO conference confirmed that the 2017 guidelines on managing chronic kidney disease–mineral and bone disorder (CKD-MBD) remain valid but proposed reframing CKD-MBD around two clinical syndromes: CKD-associated osteoporosis and CKD-associated cardiovascular disease. Future guidelines may...
Kidney International® Cutting Back on Low-value Healthcare Practices Supports Sustainable Kidney Care This mini review, part of a collaboration between ISN Emerging Leaders Program members and Kidney International® to promote green nephrology, emphasizes the urgent need for climate action, noting that healthcare contributes 5.5% of global carbon emissions. It highlights the importance of reducing low-value care...
Read all global trial selections from the ISN-ACT initiative here. The “trial of the month” is available in several languages. In addition, selected clinical trials are demystified for the layperson. ISN-ACT Global Trials Focus Subgroup member Nikolay Bulanov summarizes the design and outcomes of one of the ISN-ACT Global Trials Focus’s latest trial selections. Efficacy and safety of...
Kidney International® Executive Summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis Since the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases was published, important data concerning anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) has become available. These include the regulatory approval of avacopan for ANCA-AAV...
Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides are a heterogeneous group of rare autoimmune conditions that cause inflammation of blood vessels with various manifestations mainly involving the kidney and lung. The incidence is 10-20 cases per million population, mainly affecting people in the 5th decade of life. ANCA-associated Vasculitis includes three main diseases: granulomatosis with polyangiitis, microscopic...
